Reversal of end-stage renal failure using direct-acting antiviral agents for chronic hepatitis C

• 1 Sir Charles Gairdner Hospital, Perth, WA
• 2 University of Western Australia, Perth, WA

---

• 1. Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D. Management of patients with hepatitis C infection and renal disease. World J Hepatol 2015; 7: 213-225.
• 2. Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 2013; 369: 1035-1045.
• 3. Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology 2016; 63: 408-417.
• 4. Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385: 2502-2509.
• 5. Pockros PJ, Reddy KR, Mantry PS, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV Gt1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study [abstract LO1]. J Hepatol 2015; 62 Suppl 2: S257.